Efficacy
OCTAVE Study Design
The XELJANZ clinical development programme for ulcerative colitis includes one phase II and three phase III clinical trials of up to 12 months duration, and one ongoing long-term extension (LTE) study, OCTAVE Open.
The efficacy and safety of XELJANZ (tofacitinib citrate) for the treatment of adult patients with moderately to severely active ulcerative colitis was demonstrated in three Phase III randomised, double-blind, placebo- controlled trials (RCTs): OCTAVE Induction 1 and 2, and OCTAVE Sustain1:
    • OCTAVE Induction 1 and 2 were two identical studies of patients with moderately to severely active disease to assess the efficacy and safety of XELJANZ in inducing remission1​​​​​​​
    • OCTAVE Sustain was a study of patients who had achieved clinical response in the two OCTAVE Induction studies to assess the efficacy and safety of XELJANZ in maintaining remission1
    • Patients in the OCTAVE Phase III trial programme were eligible to enter an ongoing open-label extension study, OCTAVE Open1
    Study Designs1
    OCTAVE Induction 1 and OCTAVE Induction 2 were identical replicate studies.¹
    *Final complete efficacy assessment at week 8/52​​​​​​​
    In the OCTAVE Phase III studies, outcomes were measured for disease activity, health-related quality of life and health utility using multiple endpoints1,2

    • The primary and key secondary endpoints were clinical outcomes based on the Mayo score.
    • The Mayo endoscopic subscore, based on mucosal appearance during endoscopy, was assessed by central and local readings. Central assessment was by a central reader using video recorded during the procedure; local assessment was done by the study site investigator.​​​​​​​
    • The central reading was used for eligibility and primary efficacy endpoint analysis. The OCTAVE programme was the first in ulcerative colitis to use central reads to assess primary efficacy endpoints.
    • Local readings are more likely to reflect clinical practice where physicians use their own assessment of endoscopic findings to complement other data to make clinical decisions.
    The primary and key secondary endpoints for OCTAVE Induction 1 and 2 and OCTAVE Sustain are shown in the table below.
    ​​​​​​​
    Clinical response is also defined as it was the criteria for entry into OCTAVE Open.
    In the OCTAVE UC trials, remission was defined more stringently than in previous clinical trials for UC, by including the requirement of a rectal bleeding subscore of 0.3
    Explore more​​​​​​​
    Dosing in UC
    VISIT PAGE
    >
    BID=twice daily; LTE=long-term extension.
    References
    1.  
    2. Sandborn WJ et al. N Engl J Med 2017; 376(18): 1723–1736.
    3. XELJANZ (tofacitinib citrate) Summary of Product Characteristics.
    4. Pouillon L. Bossuyt P. Peyrin-Biroulet L. Gastroenterology 2017; 153(3): 862-864.
    5.  
    PP-XEL-GBR-3122. August 2021
    XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

    © 2021 Pfizer Pte Ltd. All rights reserved.


    The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.